Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694832 | 0.92 | MLYCD (0.72) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL4489409 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL26314066 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL7967022 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL5543209 | 0.82 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL7454658 | 0.82 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL10777907 | 0.82 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL21077862 | 0.82 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL10488234 | 0.82 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL15221192 | 0.82 | MLYCD (0.67) | MLYCDEGFRERBB2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | MLYCD 291/4885EGFR 4163/4885ERBB2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.